A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-17

Study Completion Date

2025-12-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

NCT06972459

Obesity Overweight

RECRUITING PHASE3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT06972472

Obesity Overweight Type 2 Diabetes

RECRUITING PHASE3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

NCT06993792

Obesity Overweight Type 2 Diabetes

RECRUITING PHASE3

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

NCT05872620

Obesity Overweight Type 2 Diabetes

COMPLETED PHASE3

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT05869903

Obesity Overweight Overweight or Obesity

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Orforglipron

Participants will receive orforglipron orally

Group Type EXPERIMENTAL

Orforglipron

Intervention Type DRUG

Administered orally

Placebo

Participants will receive placebo orally

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Orforglipron

Administered orally

Intervention Type DRUG

Placebo

Administered orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY3502970

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a Body Mass Index (BMI)

* ≥30.0 kilograms per square meter (kg/m2), or
* ≥27.0 kg/m2 with comorbidities

Exclusion Criteria

* Have type 1 diabetes, type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
* Have an unstable body weight within 90 days prior to screening
* Have acute or chronic hepatitis
* Are taking other medications or alternative remedies to manage weight loss

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No